CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Ferring Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc.

1:17-cv-00435

Overview

Case Number 1:17-cv-00435
Filing Date 2017-04-19
Status Terminated
Termination Date 2018-01-16
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Teva Pharmaceuticals USA, Inc. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Plaintiff

Ferring Pharmaceuticals Inc. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 8 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts Counterparts in force
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (8): CN πŸ‡ͺπŸ‡Ί Europe GB πŸ‡ΊπŸ‡Έ US 🌐 PCT
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

3 Patents

There are 3 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US8450338
Granular compositions of sodium picosulphate and potassium bicarbonate and uses thereof
Filed: 2011-09-27
Issued: 2013-05-28
Active (1.9 yrs remaining)
Expires: 2028-10-19
US8481083
Granular compositions of magnesium oxide and citric acid and uses thereof
Filed: 2008-10-10
Issued: 2013-07-09
Active (1.9 yrs remaining)
Expires: 2028-10-10
US9669110
Method for timing a colonoscopy
Filed: 2012-07-16
Issued: 2017-06-06
Active (6.0 yrs remaining) +133d PTA
Expires: 2032-11-26

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Active Threat

Active Threat β€” Patent is within enforceable statutory term; injunctive relief viable.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

23

Dispositive

0

Granted

2

Denied

0

Pending / Review

11

Motions by Category

Claim Construction / Markman Filing 8 Procedural / Extension Motion 15

Key Dispositive Motions & Rulings

Procedural / Extension Motion Pending
SO ORDERED, re 65 STIPULATION TO EXTEND TIME to file redacted version D.I. 63 to January 26, 2018. Signed by Judge Richard G. Andrews on 1/26/2018. (nms)
Entry #β€” • 2018-01-22
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME to file redacted version D.I. 63 to January 26, 2018 - filed by Teva Pharmaceuticals USA, Inc.. (Fry, David) Modified on 1/22/2018 (n...
Entry #65 • 2018-01-19 Document →
Claim Construction / Markman Filing Pending
SO ORDERED, re 62 STIPULATION and Proposed Order to Extend Time. Joint Claim Construction Chart is now due by 1/16/2018. Signed by Judge Richard G. Andrews on 1...
Entry #β€” • 2018-01-10
Procedural / Extension Motion Pending / Under Review
STIPULATION and Proposed Order to Extend Time - filed by Teva Pharmaceuticals USA, Inc.. (Fry, David) Modified on 1/10/2018 (nms). (Entered: 01/09/2018)
Entry #62 • 2018-01-09 Document →
Claim Construction / Markman Filing Pending
SO ORDERED, re 61 STIPULATION TO EXTEND TIME to file Joint Claim Construction Statement to January 9, 2018. Signed by Judge Richard G. Andrews on 1/8/2018. (nms...
Entry #β€” • 2018-01-08
Claim Construction / Markman Filing Pending / Under Review
STIPULATION TO EXTEND TIME to file Joint Claim Construction Statement to January 9, 2018 - filed by Ferring B.V., Ferring International Center S.A., Ferring Pha...
Entry #61 • 2018-01-05 Document →

Docket Entries

(137 total)
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed against Teva Pharmaceuticals USA, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2125012.) - filed by Ferring Pharmaceuticals Inc., Ferring International Center S.A.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet)(jcs) (Entered: 04/19/2017)

Entry #1 • 2017-04-19
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (jcs) (Entered: 04/19/2017)

Entry #2 • 2017-04-19
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: See Attached. Date of Expiration of Patent: October 10, 2028.Thirty Month Stay Deadline: 9/13/2019. (jcs) (Entered: 04/19/2017)

Entry #3 • 2017-04-19
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,450,338; US 8,481,083. (jcs) (Entered: 04/19/2017)

Entry #4 • 2017-04-19
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Ferring Holding S.A. for Ferring International Center S.A., Ferring Pharmaceuticals Inc. filed by Ferring International Center S.A., Ferring Pharmaceuticals Inc. (jcs) (Entered: 04/19/2017)

Entry #5 • 2017-04-19
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc